The study is designed to evaluate the efficacy and safety of a topical formulation containing Ficus awkeotsang Makino extract (FAE), derived from jelly fig, in participants with mild to moderate atopic dermatitis. Ficus awkeotsang is a traditional plant native to Taiwan.

Inclusion Criteria:

• Age ≥12 years at the time of enrollment
• Clinical diagnosis of atopic dermatitis (AD) according to the Hanifin and Rajka criteria
• Investigator's Global Assessment (IGA) score of 2 (mild) or 3 (moderate) at screening

Exclusion Criteria:

• Prior treatment with biologic agents within 16 weeks before baseline
• Use of phototherapy, systemic corticosteroids, or other systemic immunosuppressants within 28 days before baseline
• Use of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 14 days before baseline
• Presence of active skin infections
• Pregnancy or breastfeeding
• Known hypersensitivity to any component of the investigational product